*제노마인*
 
제노마인(주)는 프로테옴 연구 분야에 축적된 기술과 노하우를 바탕으로 국내의 연구자 분들과의 공동연구를 제안합니다. 제노마인(주)의 프로테오믹스 기술이 여러분의 연구에 도움이 되기를 바랍니다.

 
 
Genomine protein profiling project is open to collaborate for creating commercial profit. We offer protein expression profiling platform technology and collaborator will join with their samples or technologies. And following area is welcomed.
  • Target Identification & Validation
  • Protein Drug Identification
  • Diagnostic marker discovery
  • Disease related protein expression pattern profiling
  • Predictive Toxicology
  • Mechanism of Drug Action
  • Mass analysis of protein and peptides

If there is certain confidential information regarding your samples It is possible to enter a confidentiality agreement before submitting the request form. Material transfer agreement will be signed and sent to the sample provider after the project is approved.

In some cases, it may be more advantageous for a sample provider to enter collaboration agreements with Genomine. Genomine and the collaborator have the exclusive access right to the data generated during the collaboration. It is also possible for both parties to share profits from commercial license of the research results. This will facilitate the effort by the both parties to get maximum benefit from joint mining of the data.

 
For more information about collaboration agreement, please contact
dskimi@genomine.com
 


The collaboration agreement is summarized as follows

The collaborator retains ownership of any data and subsequent research results generated by the collaborator. Genomine retains ownership of any data and other results generated by Genomine scientists.

The collaborator and Genomine will work together to publish and patent results from the collaboration. To avoid jeopardizing patentability, each party will provide proposed publications (manuscripts, presentations, etc) to the other party for approval 30 days prior to submission for publication.

The collaborator will notify Genomine of any inventions it makes as a result of the collaboration. Genomine will cover all patent costs for inventions of interest to Genomine.

The collaborator and Genomine each get to use all results and IP from the collaboration for research purposes.

Genomine gets a first right to negotiate a commercial license to any new IP resulted from collaboration and solely owned by the collaborator. For jointly owned IP, Genomine has the right to use it non-exclusively for commercial purposes but also has an option to negotiate an exclusive commercial license. Genomine has a limited period of time within which to notify the collaborator of its interest in obtaining a license. For all commercial licenses for Genomine, the parties will agree in good faith on a reasonable financial return to the collaborator.